4LSA Stock Overview
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Athersys, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.045 |
| 52 Week High | US$1.73 |
| 52 Week Low | US$0.041 |
| Beta | -0.90 |
| 1 Month Change | 0% |
| 3 Month Change | -55.00% |
| 1 Year Change | -95.91% |
| 3 Year Change | -99.88% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4LSA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.2% |
| 1Y | -95.9% | -15.4% | 1.2% |
Return vs Industry: 4LSA underperformed the German Biotechs industry which returned -26.5% over the past year.
Return vs Market: 4LSA underperformed the German Market which returned -0% over the past year.
Price Volatility
| 4LSA volatility | |
|---|---|
| 4LSA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4LSA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 4LSA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 24 | n/a | www.athersys.com |
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications.
Athersys, Inc. Fundamentals Summary
| 4LSA fundamental statistics | |
|---|---|
| Market cap | €428.46k |
| Earnings (TTM) | -€34.24m |
| Revenue (TTM) | €73.04k |
5.9x
P/S Ratio0.0x
P/E RatioIs 4LSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4LSA income statement (TTM) | |
|---|---|
| Revenue | US$80.00k |
| Cost of Revenue | US$18.78m |
| Gross Profit | -US$18.69m |
| Other Expenses | US$18.81m |
| Earnings | -US$37.51m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | -23,368.75% |
| Net Profit Margin | -46,883.75% |
| Debt/Equity Ratio | -29.6% |
How did 4LSA perform over the long term?
See historical performance and comparison